PET imaging of 18F-(2S, 4R)4-fluoroglutamine in oncological patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037834

Enrollment

Unknown

Registered

2020-09-02

Start date

2017-08-18

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Interventions

Index test:18F-FDG

Gold Standard:18F-(2S, 4R)4-fluoroglutamine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ECoG score of 0 or 1 in age 18-70 years old; 2. Clinicians recommend pet/ct examination for the patients with tumor diagnosis and staging.

Exclusion criteria

Exclusion criteria: 1. Patients with severe abnormal liver and kidney function; 2. Pregnant, pregnant and lactating women; 3. Patients who cannot lie on their back for half an hour; 4. Patients who refuse to join this clinical study.

Design outcomes

Primary

Measure	Time frame
SUVmax;SEN, SPE, ACC, AUC of ROC;Kappa;	—

Countries

China

Contacts

Public ContactYang Zhi

Beijing Cancer Hospital

pekyz@163.com+86 13701382886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026